The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer

Overview

Journal Breast Care (Basel)

Publisher Karger

Date 2018 Jun 29

PMID 29950962

Citations 94

Authors

Andre Steven

Barbara Seliger

Affiliations

Soon will be listed here.

Abstract

While detailed analysis of aberrant cancer cell signaling pathways and changes in cancer cell DNA has dominated the field of breast cancer biology for years, there now exists increasing evidence that the tumor microenvironment (TME) including tumor-infiltrating immune cells support the growth and development of breast cancer and further facilitate invasion and metastasis formation as well as sensitivity to drug therapy. Furthermore, breast cancer cells have developed different strategies to escape surveillance from the adaptive and innate immune system. These include loss of expression of immunostimulatory molecules, gain of expression of immunoinhibitory molecules such as PD-L1 and HLA-G, and altered expression of components involved in apoptosis. Furthermore, the composition of the TME plays a key role in breast cancer development and treatment response. In this review we will focus on i) the different immune evasion mechanisms used by breast cancer cells, ii) the role of immune cell infiltration in this disease, and (iii) implication for breast cancer-based immunotherapies.

Citing Articles

NOL-7 serves as a potential prognostic-related biomarker for hepatocellular carcinoma.

Lei Q, Huang Y, Deng F, Zheng H, Hong X, Wang P Discov Oncol. 2025; 16(1):69.

PMID: 39836310 PMC: 11751243. DOI: 10.1007/s12672-024-01551-7.

Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities.

Garrido M, Navarro-Ocon A, Ronco-Diaz V, Olea N, Aptsiauri N Genes (Basel). 2025; 15(12.

PMID: 39766811 PMC: 11675875. DOI: 10.3390/genes15121542.

Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles.

Muhammad F, Altalbawy F, Mandaliya V, Saraswat S, Rekha M, Aulakh D Clin Transl Oncol. 2024; .

PMID: 39692807 DOI: 10.1007/s12094-024-03793-x.

A pan-cancer analysis of the oncogenic function of HMGB1 in human tumors.

Yang H, Zhao X, Li X, Wang X, Pu Y, Wei D Biochem Biophys Rep. 2024; 40:101851.

PMID: 39582753 PMC: 11584604. DOI: 10.1016/j.bbrep.2024.101851.

Systematic pan-cancer analysis of the prognostic value of MECOM in human cancer.

Lu Y, Quan J, Liu F, Huang B Discov Oncol. 2024; 15(1):694.

PMID: 39576394 PMC: 11584820. DOI: 10.1007/s12672-024-01599-5.

References

Bergmann-Leitner E, Abrams S . Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions. Cell Immunol. 2001; 209(1):49-62. DOI: 10.1006/cimm.2001.1781. View

Zhang H, Xiang R, Wu B, Li J, Luo G . T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: Clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes. Mol Clin Oncol. 2017; 7(4):557-563. PMC: 5574202. DOI: 10.3892/mco.2017.1360. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Ibrahim M, Scozzi D, Toth K, Ponti D, Kreisel D, Menna C . Naive CD4 T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion. J Immunol. 2017; 200(2):847-856. PMC: 5760318. DOI: 10.4049/jimmunol.1700396. View

Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H . Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 2011; 11:454. PMC: 3214195. DOI: 10.1186/1471-2407-11-454. View

Garrido F, Cabrera T, Aptsiauri N . "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010; 127(2):249-56. DOI: 10.1002/ijc.25270. View

Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M . Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25(8):1536-43. DOI: 10.1093/annonc/mdu191. View

Nicolini A, Ferrari P, Duffy M . Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2017; 52(Pt 1):56-73. DOI: 10.1016/j.semcancer.2017.08.010. View

Devarajan E, Sahin A, Chen J, Krishnamurthy R, Aggarwal N, Brun A . Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002; 21(57):8843-51. DOI: 10.1038/sj.onc.1206044. View

10.

Perou C, Jeffrey S, van de Rijn M, Rees C, Eisen M, Ross D . Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999; 96(16):9212-7. PMC: 17759. DOI: 10.1073/pnas.96.16.9212. View

11.

Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V . Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. J Immunol Res. 2016; 2016:4326495. PMC: 5019910. DOI: 10.1155/2016/4326495. View

12.

Garrido F, Algarra I, Garcia-Lora A . The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother. 2010; 59(10):1601-6. PMC: 11029827. DOI: 10.1007/s00262-010-0893-2. View

13.

Petitprez F, Vano Y, Becht E, Giraldo N, De Reynies A, Sautes-Fridman C . Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunol Immunother. 2017; 67(6):981-988. PMC: 11028160. DOI: 10.1007/s00262-017-2058-z. View

14.

Ryschich E, Cebotari O, Fabian O, Autschbach F, Kleeff J, Friess H . Loss of heterozygosity in the HLA class I region in human pancreatic cancer. Tissue Antigens. 2004; 64(6):696-702. DOI: 10.1111/j.1399-0039.2004.00324.x. View

15.

Shokouh T, Ezatollah A, Barand P . Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study. Medicine (Baltimore). 2015; 94(32):e1359. PMC: 4616694. DOI: 10.1097/MD.0000000000001359. View

16.

Hoff E, Tubbs R, Myles J, Procop G . HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002; 117(6):916-21. DOI: 10.1309/4NTU-N6K4-F8JF-EWRX. View

17.

Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H . The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13):5405-13. DOI: 10.1158/0008-5472.CAN-07-5206. View

18.

Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F . Mechanism of immune evasion in breast cancer. Onco Targets Ther. 2017; 10:1561-1573. PMC: 5359138. DOI: 10.2147/OTT.S126424. View

19.

Hanalioglu D, Ayvaz D, Turul Ozgur T, van der Burg M, Sanal O, Tezcan I . A novel mutation in TAP1 gene leading to MHC class I deficiency: Report of two cases and review of the literature. Clin Immunol. 2017; 178:74-78. DOI: 10.1016/j.clim.2017.01.011. View

20.

Yan J, Liu X, Han L, Xiao G, Li N, Deng Y . Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev. 2015; 16(2):823-9. DOI: 10.7314/apjcp.2015.16.2.823. View